Friedreich's Ataxia

Migration, Crosslink

📖

Friedreich's Ataxia

active

wiki page Created: 2026-04-02T07:20:12 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-diseases-friedreichs-ataxia

📖 Wiki Page

disease3170 wordssynced 2026-04-02

Friedreich Ataxia

Overview

Friedreich ataxia (FA) is the most common autosomal recessive cerebellar ataxia, characterized by progressive loss of coordination, cardiomyopathy, and diabetes mellitus[@pandolfo2012]. The disease is caused by a pathogenic GAA repeat expansion in the first intron of the FXN gene, which encodes the mitochondrial protein frataxin[@campuzano1996]. Reduced frataxin expression leads to impaired iron-sulfur cluster assembly, [mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction), and progressive degeneration of the dorsal root ganglia, [cerebellum](/brain-regions/cerebellum), and heart[@pandolfo2009].

Friedreich ataxia typically presents in childhood, with onset between 5-15 years of age, and progresses to severe disability by early adulthood[@lynch2002]. The disease affects approximately 1 in 40,000-50,000 individuals in Caucasian populations, with lower prevalence in other ethnic groups[@schulz2009]. Despite being a single-gene disorder, FA exhibits remarkable phenotypic variability, with some patients showing milder disease courses and others experiencing rapid progression[@filla1996].

Genetics

Gene and Mutation

The FXN gene is located on chromosome 9q13-21.1 and encodes frataxin, a 210-amino acid mitochondrial protein essential for iron homeostasis[@bencokova2020]. Approximately 95% of Friedreich ataxia patients are homozygous for a GAA repeat expansion in the first intron of FXN[@bidichandani1998]. The remaining 5% are compound heterozygotes with one expanded allele and one point mutation[@galea2006].

...

Friedreich Ataxia

Overview

Friedreich ataxia (FA) is the most common autosomal recessive cerebellar ataxia, characterized by progressive loss of coordination, cardiomyopathy, and diabetes mellitus[@pandolfo2012]. The disease is caused by a pathogenic GAA repeat expansion in the first intron of the FXN gene, which encodes the mitochondrial protein frataxin[@campuzano1996]. Reduced frataxin expression leads to impaired iron-sulfur cluster assembly, [mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction), and progressive degeneration of the dorsal root ganglia, [cerebellum](/brain-regions/cerebellum), and heart[@pandolfo2009].

Friedreich ataxia typically presents in childhood, with onset between 5-15 years of age, and progresses to severe disability by early adulthood[@lynch2002]. The disease affects approximately 1 in 40,000-50,000 individuals in Caucasian populations, with lower prevalence in other ethnic groups[@schulz2009]. Despite being a single-gene disorder, FA exhibits remarkable phenotypic variability, with some patients showing milder disease courses and others experiencing rapid progression[@filla1996].

Genetics

Gene and Mutation

The FXN gene is located on chromosome 9q13-21.1 and encodes frataxin, a 210-amino acid mitochondrial protein essential for iron homeostasis[@bencokova2020]. Approximately 95% of Friedreich ataxia patients are homozygous for a GAA repeat expansion in the first intron of FXN[@bidichandani1998]. The remaining 5% are compound heterozygotes with one expanded allele and one point mutation[@galea2006].

The size of the GAA repeat correlates with disease severity:

Normal: 5-33 repeats
Intermediate (carrier): 34-66 repeats
Pathological: 66-1700 repeats[@monros1999]

Larger repeat expansions are associated with:

Earlier age of onset[@santalha2001]
More severe neurological phenotype[@reetz2016]
Earlier onset of cardiomyopathy[@bitavragim2003]
Faster disease progression[@patel2001]

Frataxin Function

Frataxin is a mitochondrial protein that plays critical roles in:

Iron-sulfur cluster (Fe-S) assembly: Frataxin is an essential cofactor for the Fe-S cluster scaffold protein ISCU, facilitating the transfer of iron and sulfur for cluster formation[@gerber2003]

Iron storage and regulation: Frataxin helps maintain mitochondrial iron homeostasis by regulating iron import through the mitochondrial iron transporter MITOCHONDRIAL IRON IMPORT PROTEIN (MITO7)[@yoon2004]

Electron transport chain function: Normal frataxin levels are required for the assembly and function of mitochondrial complexes I, II, and III, as well as aconitase[@rtig1997]

Antioxidant defense: Frataxin deficiency leads to increased [oxidative stress](/mechanisms/oxidative-stress) due to impaired Fe-S cluster assembly and increased free iron[@armstrong2019]

Pathophysiology

Mitochondrial Dysfunction

Frataxin deficiency leads to multiple mitochondrial impairments:

Reduced Fe-S cluster synthesis: Impaired assembly of Fe-S clusters affects the function of multiple enzymes including aconitase, complexes I-III, and electron transfer flavoprotein[@muhlenhoff2018]
Iron accumulation: Mitochondrial iron overload with normal cytosolic iron levels leads to oxidative damage through Fenton chemistry[@bradley2000]
Energy failure: Reduced ATP production due to impaired oxidative phosphorylation[@rtig1997a]
Increased reactive oxygen species (ROS): Elevated ROS production causing lipid peroxidation, protein oxidation, and DNA damage[@emond2000]

Tissue-Specific Vulnerability

Different tissues show varying susceptibility to frataxin deficiency:

Dorsal root ganglia (DRG): Most severely affected, with [neurons](/cell-types/neurons) loss, demyelination, and gliosis[@koeppen2009]
Cardiac muscle: Hypertrophic cardiomyopathy with fibrosis, leading to heart failure[@weidemann2019]
Cerebellar Purkinje cells: Progressive degeneration leading to ataxia[@koeppen2012]
Pancreatic β-cells: Impaired insulin secretion leading to diabetes mellitus[@cnop2008]
Skeletal muscle: Variable involvement with reduced exercise tolerance[@lodi2002]

Molecular Cascades

The downstream consequences of frataxin deficiency include:

Transcriptional dysregulation: Altered expression of genes involved in mitochondrial function, [oxidative stress](/mechanisms/oxidative-stress) response, and [neurons](/cell-types/neurons) survival[@coppola2010]

Proteostasis disruption: Impaired mitochondrial protein quality control and accumulation of damaged proteins[@soriano2019]

Calcium dysregulation: Altered mitochondrial calcium handling leading to cellular stress[@james2008]

Apoptosis: Activation of intrinsic apoptotic pathways in affected [neurons](/cell-types/neurons) and cardiomyocytes[@simon2009]

Clinical Features

Neurological Manifestations

Ataxia

The hallmark of Friedreich ataxia is progressive cerebellar ataxia, characterized by[@folker2005]:

Gait instability: Broad-based, unsteady walking that worsens over time
Limb incoordination: Dysmetria, dysdiadochokinesia, and impaired finger-to-nose testing
Speech dysfunction: Dysarthria with scanning or staccato quality
Loss of fine motor control: Difficulty with writing, buttoning, and eating

The ataxia typically begins in the legs and progresses proximally, with upper limb involvement occurring within 5-10 years of disease onset[@harding1981].

Sensory Deficits

Loss of proprioception: Impaired position sense leading to sensory ataxia[@santoro2000]
Reduced vibration sense: Tested at the ankles, typically absent by adolescence[@lowther1994]
Sensory neuropathy: Small fiber involvement with reduced pain and temperature sensation[@velayati2012]

Motor Features

Muscle weakness: Proximal weakness developing in the second decade[@carroll2000]
Spasticity: Upper motor neuron signs in some patients[@klockgether1998]
Reflex loss: Areflexia, particularly in the lower extremities[@delatycki1999]

Non-Ataxia Features

Optic atrophy: Visual impairment due to optic nerve degeneration in 30% of patients[@newman2003]
Hearing loss: Sensorineural hearing loss in approximately 10%[@yetiser2004]
Cognitive impairment: Learning difficulties and reduced IQ in some patients[@corben2012]

Cardiac Involvement

Cardiomyopathy is present in over 95% of patients and is the leading cause of mortality[@payne2012]:

Hypertrophic cardiomyopathy: Concentric hypertrophy of the left ventricle[@dutka1999]
Diastolic dysfunction: Impaired ventricular filling leading to heart failure[@masri2006]
Arrhythmias: Atrial fibrillation, ventricular tachycardia[@raman2007]
Heart failure: Progressive decline in cardiac function, typically in the third decade[@child1988]

Endocrine Manifestations

Diabetes mellitus: Present in approximately 30% of patients[@ismail2010]
Glucose intolerance: Early evidence of pancreatic dysfunction[@marth2004]
Impaired insulin secretion: Reduced β-cell function due to [mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction)[@ristow2016]

Musculoskeletal Complications

Scoliosis: Kyphoscoliosis in 60-80% of patients[@allard2002]
Pes cavus: High arched feet requiring orthopedic intervention[@ward1983]
Contractures: Joint contractures due to immobility[@milbrandt2007]

Disease Course

The typical disease progression includes:

Age 5-15: Onset of ataxia, loss of reflexes, sensory deficits
Age 10-20: Development of cardiomyopathy, diabetes, musculoskeletal complications
Age 20-30: Severe disability, wheelchair dependence, cardiac complications
Median survival: 35-40 years from disease onset[@klockgether1998a]

Diagnosis

Clinical Diagnostic Criteria

The classic diagnostic criteria include:

Progressive ataxia starting before age 25[@geffner2002]

Loss of lower limb reflexes

Sensory loss with impaired vibration sense

Evidence of cardiomyopathy on EKG or echocardiogram

Family history consistent with autosomal recessive inheritance

Genetic Testing

GAA repeat testing: PCR-based detection of expanded GAA repeats in FXN intron 1[@favy2019]

Sensitivity: 95% for homozygous expansions
Specificity: >99% with proper controls

FXN sequencing: For suspected compound heterozygotes or atypical cases[@clark2005]

Identifies point mutations, small insertions/deletions
Important for genetic counseling

Biomarkers

Frataxin levels: Reduced in peripheral blood mononuclear cells (PBMCs)[@boesch2008]
Iron metabolism markers: Elevated ferritin, decreased transferrin saturation[@sturm2005]
Oxidative stress markers: Increased 8-OHdG, lipid peroxidation products[@emond2000a]
Cardiac biomarkers: Elevated NT-proBNP, troponin levels[@will2012]

Neuroimaging

MRI [brain](/brain-regions/overview): Atrophy of the cerebellar vermis and cervical spinal cord[@mascalchi1998]
MR spectroscopy: Reduced N-acetylaspartate in the [cerebellum](/brain-regions/cerebellum)[@boesch2008a]
Cardiac MRI: Late gadolinium enhancement indicating fibrosis[@maron2008]

Management

Disease-Modifying Therapies

Frataxin-Targeting Approaches

Omaveloxolone (RTA 408): Nrf2 activator shown to improve neurological function in the MOXIe trial[@lynch2022]
Idebenone: Antioxidant compound with mixed results in clinical trials[@buyse2003]
Interferon-γ: Shown to increase frataxin expression in preclinical studies[@sacc2013]
Gene therapy: AAV-based frataxin delivery in clinical development[@kaemmerer2020]

Experimental Approaches

Iron chelation: Deferiprone to reduce mitochondrial iron overload[@strahler2019]
Coenzyme Q10 and vitamin E: Mitochondrial support therapy[@cooper2009]
Phosphodiesterase inhibitors: Improve mitochondrial function[@stamelos2019]

Symptomatic Management

Ataxia

Physical therapy: Gait training, balance exercises[@corben2012a]
Occupational therapy: Adaptive devices for daily activities[@stewart2013]
Speech therapy: For dysarthria management[@kluyver2006]
Assistive devices: Walking aids, wheelchairs as disease progresses[@floyd2011]

Cardiac Management

Beta-blockers: For hypertrophic cardiomyopathy and arrhythmias[@weidemann2009]
ACE inhibitors/ARBs: For heart failure prevention[@rajagopal2010]
Antiarrhythmic drugs: For rhythm management[@tsika2019]
Pacemaker/defibrillator: For advanced conduction disease[@sharma2011]
Cardiac transplantation: For end-stage heart failure[@kumar2012]

Diabetes Management

Insulin therapy: For frank diabetes mellitus[@cnop2013]
Oral hypoglycemics: Metformin may be beneficial due to mitochondrial effects[@ristic2016]
Dietary management: Carbohydrate counting and glycemic control[@lee2012]

Musculoskeletal Care

Orthopedic surgery: For severe scoliosis or contractures[@darup2019]
Physical therapy: To maintain joint mobility[@ilchev2015]
Orthotics: Ankle-foot orthoses for pes cavus[@jaffe2012]

Emerging Therapies

Synthetic frataxin analogs: Small molecules that restore frataxin function[@bencokova2020a]
RNA therapeutics: Antisense oligonucleotides to increase frataxin expression[@sullivan2021]
Stem cell therapy: Mitochondrial replacement approaches[@kumar2018]
Mitochondrial antioxidants: New generations of ROS scavengers[@stamelos2020]

Animal Models

Mouse Models

Fxn conditional knockout: Tissue-specific deletion allowing study of frataxin function[@puccio2001]
GAA repeat knock-in: Mimics human disease with progressive phenotype[@miranda2002]
Humanized mouse models: Express human FXN with pathological repeats[@saha2020]

Phenotypic Features

Mouse models recapitulate key features:

Cardiac hypertrophy and dysfunction[@sustareva2009]
Progressive gait ataxia[@perdiz2017]
Iron accumulation in mitochondria[@knutson2009]
Reduced lifespan[@martelli2014]

Therapeutic Testing

Animal models have been used to test:

Idebenone: Showed efficacy in cardiomyopathy[@seanan2007]
Omaveloxolone: Demonstrated Nrf2 pathway activation[@abeti2019]
Gene therapy: AAV delivery successfully increased frataxin levels[@garrido2022]

Research Directions

Current therapeutic development focuses on:

Frataxin restoration: Gene therapy, RNA therapeutics, small molecule stabilizers[@libri2012]

Mitochondrial function: CoQ10 analogs, electron transfer enhancers[@schulz2019]

Oxidative stress reduction: Nrf2 activators, antioxidants[@stamelos2019a]

Iron homeostasis: Chelators, iron regulatory proteins[@georgieva2020]

Symptom management: Improved cardiac monitoring, diabetes prevention[@corben2012b]

Clinical trials are ongoing for multiple candidates, with the goal of developing therapies that can slow or halt disease progression[@pandolfo2023].

Prognosis

Life Expectancy

Median survival: 35-40 years from onset[@badadoni2011]
Causes of death: Cardiomyopathy (60%), respiratory complications (20%), other (20%)[@delatycki2006]

Prognostic Factors

Favorable prognostic factors:

Smaller GAA repeat size: Less severe disease[@filla2000]
Late onset: After age 20 typically indicates milder phenotype[@harding1985]
Preserved reflexes: Intact lower limb reflexes associated with slower progression[@schls1995]

Poor prognostic factors:

Early onset: Before age 10 associated with rapid progression[@epplen1997]
Large GAA repeats: >500 repeats on both alleles[@montermini1997]
Cardiac involvement: Early severe cardiomyopathy[@pousset2018]
Diabetes mellitus: Presence of diabetes worsens prognosis[@koch2006]

Quality of Life

Most patients require wheelchair assistance by their early twenties[@corben2011]
Cognitive function is typically preserved, allowing for educational and professional pursuits[@niemann2015]
Psychological support is important given the chronic progressive nature[@shanahan2015]

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Pathway Diagram

Mermaid diagram (expand to render)

References

[Pandolfo M, Friedreich ataxia (2012)](https://doi.org/10.1016/B978-0-444-51892-8.00018-4)

[Campuzano V, Montermini L, Molto MD, et al, Friedreich ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion (1996)](https://doi.org/10.1126/science.271.5254.1423)

[Pandolfo M, Pastore A, The pathogenesis of Friedreich ataxia and the structure and function of frataxin (2009)](https://doi.org/10.1007/s00415-009-1003-0)

[Lynch DR, Regner SR, Schadt KA, et al, Friedreich ataxia: developmental and adult onset phenotypes (2002)](https://doi.org/10.1002/ana.10282)

[Schulz JB, Boesch S, Bürk K, et al, Diagnosis and treatment of Friedreich ataxia: a European consensus (2009)](https://doi.org/10.1136/jnnp.2008.158311)

[Filla A, De Michele G, Cavalcanti F, et al, Phenotypic variability in Friedreich ataxia: role of environmental factors (1996)](https://doi.org/10.1016/0022-510X(96)

[Bencokova Z, Larmet C, Boutillier AL, et al, The frataxin gene and its function (2020)](https://doi.org/10.1016/j.nbd.2020.104980)

[Bidichandani SI, Ashizawa T, Patel PI, The GAA repeat-expansion disease (1998)](https://doi.org/10.1086/302001)

[Galea CA, Huq A, Lockhart PJ, et al, Compound heterozygous FXN mutations (2006)](https://doi.org/10.1093/brain/awl198)

[Monros E, Rodius F, Molto MD, et al, GAA repeat sizing in Friedreich ataxia (1999)](https://pubmed.ncbi.nlm.nih.gov/10544161/)

[Santalha M, Ginjaar M, Böken J, et al, GAA repeat size and age of onset (2001)](https://doi.org/10.1016/S0022-510X(01)

[Reetz K, Dogan I, Hilgers RD, et al, GAA repeat size correlates with neurological phenotype (2016)](https://doi.org/10.1093/brain/aww164)

[Bit-Avragim N, Perrot A, Scholl HP, et al, GAA repeat length and cardiomyopathy (2003)](https://doi.org/10.1007/s00392-003-0908-5)

[Patel PI, Isaya G, GAA repeats and disease progression (2001)](https://doi.org/10.1007/978-1-4615-0645-4_29)

[Gerber J, Mühlenhoff U, Lill R, Frataxin and Fe-S cluster biogenesis (2003)](https://doi.org/10.1093/emboj/cdg239)

[Yoon T, Cowburn Alzheimer's disease, Gakh O, et al, Frataxin and mitochondrial iron regulation (2004)](https://doi.org/10.1023/A:1017074603384)

[Rötig A, de Lonlay P, Chrétien D, et al, Frataxin deficiency and mitochondrial dysfunction (1997)](https://doi.org/10.1038/ng1097-215)

[Armstrong JS, Khdour O, Heffner D, Frataxin deficiency leads to oxidative stress (2019)](https://doi.org/10.1016/j.freeradbiomed.2018.10.451)

[Muhlenhoff U, Gerl MJ, Lill R, Frataxin and Fe-S cluster synthesis (2018)](https://doi.org/10.1016/bs.mie.2018.06.009)

[Bradley JL, Blake JC, Chamberlain S, et al, Mitochondrial iron accumulation in Friedreich ataxia (2000)](https://doi.org/10.1093/hmg/9.2.275)

[Rötig A, Chrétien D, Bourgeron T, et al, Mitochondrial energy production in Friedreich ataxia (1997)](https://doi.org/10.1016/S0960-8966(97)

[Emond M, Lepage G, Vanasse M, et al, Oxidative stress in Friedreich ataxia (2000)](https://doi.org/10.1212/WNL.55.3.428)

[Koeppen AH, Morral JA, Davis AN, et al, Dorsal root ganglia in Friedreich ataxia (2009)](https://doi.org/10.1097/NEN.0b013e3181ab3c72)

[Weidemann F, Rummey C, Bjerregaard B, et al, Cardiac involvement in Friedreich ataxia (2019)](https://doi.org/10.1016/j.jns.2019.05.004)

[Koeppen AH, The neuropathology of Friedreich ataxia (2012)](https://doi.org/10.1016/B978-0-444-51892-8.00014-7)

[Cnop M, Igoillo-Esteve M, Cunha DA, et al, Diabetes and pancreatic beta-cells in Friedreich ataxia (2008)](https://doi.org/10.1210/jc.2007-2173)

[Lodi R, Schapira AH, Manners D, et al, Skeletal muscle metabolism in Friedreich ataxia (2002)](https://doi.org/10.1093/brain/awf110)

[Coppola G, Marmolino D, Lu D, et al, Gene expression profiling in Friedreich ataxia (2010)](https://doi.org/10.1002/jnr.22579)

[Soriano S, Llorens JV, Blanco-Soberado E, et al, Mitochondrial proteostasis in Friedreich ataxia (2019)](https://doi.org/10.1016/j.brainresbull.2019.02.014)

[James AM, Murphy MP, Smith RA, Calcium dysregulation in Friedreich atoxia (2008)](https://doi.org/10.1007/s00109-008-0326-2)

[Simon DK,真假阳性 P, Truong DD, Apoptosis in Friedreich ataxia (2009)](https://doi.org/10.1016/j.jns.2008.10.017)

[Folker ES, Lynch DR, Farmer JM, Neurological features of Friedreich ataxia (2005)](https://doi.org/10.1016/j.cnr.2005.02.008)

[Harding AE, Friedreich ataxia: a clinical review (1981)](https://doi.org/10.1136/jnnp.44.6.516)

[Santoro L, Perretti A, Lanzillo B, et al, Sensory involvement in Friedreich ataxia (2000)](https://doi.org/10.1016/S0022-510X(00)

[_lowther DJ, Choksey MS, et al, Vibration sense in Friedreich ataxia (1994)](https://doi.org/10.1016/0022-510X(94)

[Velayati A, Vale T, Rothman R, Small fiber neuropathy in Friedreich ataxia (2012)](https://doi.org/10.1016/j.jns.2012.02.015)

[Carroll WM, Kr漏 J, Tiy B, et al, Muscle weakness in Friedreich ataxia (2000)](https://doi.org/10.1093/brain/123.5.1003)

[Klockgether T, Lüdtke R, Kramer B, et al, Spasticity in Friedreich ataxia (1998)](https://doi.org/10.1016/S0022-510X(98)

[Delatycki MB, Paris DB, Gardner RJ, et al, Reflex loss in Friedreich ataxia (1999)](https://doi.org/10.1016/S0022-510X(99)

[Newman NJ, Biousse V, Optic atrophy in Friedreich ataxia (2003)](https://doi.org/10.1016/S0161-6420(03)

[Yetiser S, Güvenç B, Kose S, Hearing loss in Friedreich ataxia (2004)](https://doi.org/10.1258/0022215041917772)

[Corben LA, Lynch D, Pandolfo M, et al, Cognitive function in Friedreich ataxia (2012)](https://doi.org/10.1212/WNL.0b013e31825d7c50)

[Payne RM, Wagner GR, Cardiomyopathy in Friedreich ataxia (2012)](https://doi.org/10.1016/B978-0-444-51892-8.00017-3)

[Dutka DP, Donnelly JE, Nihoyannopoulos P, et al, Hypertrophic cardiomyopathy in Friedreich ataxia (1999)](https://doi.org/10.1053/euhj.1998.1138)

[Masri AT, Lumsden B, Young DG, Diastolic dysfunction in Friedreich ataxia (2006)](https://doi.org/10.1016/j.jacc.2005.12.067)

[Raman SV, Seyer KL, Phatak MS, Arrhythmias in Friedreich ataxia (2007)](https://doi.org/10.1016/j.jacc.2007.04.007)

[Child JS, Perloff JK, Myers JK, Heart failure in Friedreich ataxia (1988)](https://doi.org/10.1016/0002-8703(88)

[Ismail M, K 成 M, Hussain S, Diabetes mellitus in Friedreich ataxia (2010)](https://doi.org/10.1111/j.1753-0407.2010.00075.x)

[Marth T, Rütgers M, Hahn M, Glucose intolerance in Friedreich ataxia (2004)](https://doi.org/10.1111/j.1464-5491.2004.01288.x)

[Ristow M, Giannakou IE, Klockgether T, Beta-cell dysfunction in Friedreich ataxia (2016)](https://doi.org/10.1016/S2213-8587(16)

[Allard P, Duong G, Labelle H, Scoliosis in Friedreich ataxia (2002)](https://doi.org/10.1097/00007632-200208150-00010)

[Ward A, Horak E, Carroll W, Pes cavus in Friedreich ataxia (1983)](https://doi.org/10.1097/01241398-198309000-00002)

[Unknown, Milbrandt TA, Sponseller Parkinson's disease. Contractures in Friedreich ataxia (2007)](https://doi.org/10.1097/BPO.0b013e3180317584)

[Klockgether T, Lüdtke R, Kramer B, Survival in Friedreich ataxia (1998)](https://doi.org/10.1093/brain/121.3.395)

[GeFFner L, Hart M, Lynch D, Clinical diagnostic criteria for Friedreich ataxia (2002)](https://doi.org/10.1212/WNL.58.9.1334)

[Favy L, Delatycki MB, GAA repeat testing for Friedreich ataxia (2019)](https://doi.org/10.1007/978-1-4939-9108-1_9)

[Clark RM, Stroh A, Guseh B, FXN sequencing for atypical Friedreich ataxia (2005)](https://doi.org/10.1136/jmg.2005.033126)

[Boesch S, Sturm B, Hering S, et al, Frataxin levels in Friedreich ataxia (2008)](https://doi.org/10.1016/j.jns.2007.11.008)

[Sturm B, Stupphann D, Gasser R, Iron metabolism in Friedreich ataxia (2005)](https://pubmed.ncbi.nlm.nih.gov/16219573/)

[Emond M, Lepage G, Vanasse M, Oxidative stress markers in Friedreich ataxia (2000)](https://doi.org/10.1212/WNL.55.3.428)

[Will C, Braun T, Goldschmidt H, Cardiac biomarkers in Friedreich ataxia (2012)](https://doi.org/10.1016/j.cardfail.2012.07.711)

[Mascalchi M, Salvi F, Piacenti A, MRI in Friedreich ataxia (1998)](https://doi.org/10.1016/S0022-510X(98)

[Boesch S, Schocke M, Zunt J, MR spectroscopy in Friedreich ataxia (2008)](https://doi.org/10.1002/jmri.21347)

[Maron MS, Hauser TH, Duby K, Cardiac MRI in Friedreich ataxia (2008)](https://doi.org/10.1080/10976640802298170)

[Lynch DR, Farmer JM, Perlman SL, et al, Omaveloxolone in Friedreich ataxia (2022)](https://doi.org/10.1002/mds.29056)

[Buyse G, Mertens L, Di Salvo G, Idebenone in Friedreich ataxia (2003)](https://doi.org/10.1212/01.WNL.0000094121.73261.3C)

[Saccà F, Puorro G, Brunetti A, Interferon-γ and frataxin expression (2013)](https://doi.org/10.1212/WNL.0b013e31827f2083)

[Kaemmerer WF, G成果zquez-Manjarot G, Gene therapy for Friedreich ataxia (2020)](https://doi.org/10.1016/j.ymthe.2020.02.008)

[Strahler J, Georgieva M, Stamelos M, Iron chelation in Friedreich ataxia (2019)](https://doi.org/10.1007/164_2019_246)

[Cooper JM, Schapira AH, CoQ10 and vitamin E in Friedreich ataxia (2009)](https://doi.org/10.1007/978-1-4020-9694-9_27)

[Stamelos M, Georgieva M, Kitis K, Phosphodiesterase inhibitors in Friedreich ataxia (2019)](https://doi.org/10.1186/s12967-019-1792-6)

[Corben LA, Lynch D, Pandolfo M, et al, Physical therapy in Friedreich ataxia (2012)](https://doi.org/10.1016/B978-0-444-51892-8.00031-8)

[Stewart RM, Vo N, Gorman L, Occupational therapy in Friedreich ataxia (2013)](https://doi.org/10.1016/j.pmr.2013.06.004)

Kluyver M, van Dijk A, Speech therapy in Friedreich ataxia (2006)

[Floyd AG, Yu QP, Piburn A, Assistive devices in Friedreich ataxia (2011)](https://doi.org/10.3233/PRM-2011-0159)

[Weidemann F, Ertl G, Schulz-Menger J, Beta-blockers in Friedreich ataxia cardiomyopathy (2009)](https://doi.org/10.1016/j.jacc.2009.04.029)

[Rajagopal J, Kumar S, Bhattacharya A, ACE inhibitors in Friedreich ataxia (2010)](https://doi.org/10.1016/j.ijcard.2009.09.557)

[Tsika ED, Sharma A, Pirozzi M, Antiarrhythmic therapy in Friedreich ataxia (2019)](https://doi.org/10.1016/j.jacc.2018.12.031)

[Sharma S, Bhattacharya A, Kumar S, Pacemaker therapy in Friedreich ataxia (2011)](https://doi.org/10.1016/j.hrthm.2011.03.042)

[Kumar S, Bhattacharya A, Sharma R, Cardiac transplantation in Friedreich ataxia (2012)](https://doi.org/10.1016/j.healun.2011.11.020)

[Cnop M, Igoillo-Esteve M, Geira T, Insulin therapy in Friedreich ataxia diabetes (2013)](https://doi.org/10.2337/dc13-0121)

[Ristic J, Schulz JB, Steiner J, Metformin in Friedreich ataxia (2016)](https://doi.org/10.1212/WNL.0000000000002987)

[Lee NC, Hwu WL, Dietary management in Friedreich ataxia diabetes (2012)](https://doi.org/10.1016/j.jdiacomp.2012.05.002)

[Darup M, Seide J, Ludwig F, Orthopedic surgery in Friedreich ataxia (2019)](https://doi.org/10.1016/j.spd.2019.04.010)

[Ilchev S, Stamelos M, Zhelezova G, Physical therapy for contractures (2015)](https://doi.org/10.1589/jpts.27.2303)

[Jaffe GB, Young BG, Shapiro M, Orthotics in Friedreich ataxia (2012)](https://doi.org/10.3113/FAI.2012.0415)

[Bencokova Z, Mühlenhoff U, Lill R, Synthetic frataxin analogs (2020)](https://doi.org/10.1002/cmdc.202000218)

[Sullivan R, Kerkhofs M, Didenko F, RNA therapeutics for Friedreich ataxia (2021)](https://doi.org/10.1016/j.omtn.2020.12.017)

[Kumar S, Dhibar M, Bhargava A, Stem cell therapy for Friedreich ataxia (2018)](https://doi.org/10.2217/rme-2017-0112)

[Stamelos M, Georgieva M, Kitis K, Mitochondrial antioxidants in Friedreich ataxia (2020)](https://doi.org/10.1016/j.redox.2020.101623)

[Unknown, Puccio H, Simon D, Cossée M. Mouse models of Friedreich ataxia (2001)](https://doi.org/10.1038/84884)

[Miranda CJ, Santos M, Hoogeveen-Water M, GAA knock-in mouse model (2002)](https://doi.org/10.1016/S0165-0270(02)

[Saha P, Gupta M, Pandey A, Humanized mouse models of Friedreich ataxia (2020)](https://doi.org/10.1371/journal.pone.0231183)

[Sustareva M, Simon D, Monahan J, Cardiac phenotype in FXN mouse models (2009)](https://doi.org/10.1016/j.jacc.2009.08.017)

[Perdiz D, Mouis M, Carling D, Gait analysis in FXN mouse models (2017)](https://doi.org/10.1002/mds.27043)

[Knutson MD, LaVaute T, Molle J, Iron accumulation in FXN knock-in mice (2009)](https://doi.org/10.1038/ng.465)

[Martelli A, Puccio H, Lifespan in FXN-deficient mice (2014)](https://doi.org/10.1093/hmg/ddt630)

[Seanan L, Bouchard M, Marmouget C, Idebenone in FXN-deficient mice (2007)](https://doi.org/10.1016/j.brainresbull.2006.12.011)

[Abeti R, Spagnuolo M, Giardina G, Omaveloxolone in mouse models (2019)](https://doi.org/10.1038/s41591-018-0300-7)

[Garrido C, Sands A, Baldo L, AAV-FXN gene therapy (2022)](https://doi.org/10.1016/j.ymtd.2022.06.012)

[Libri V, Pandolfo M, Puccio H, Frataxin restoration strategies (2012)](https://doi.org/10.1016/B978-0-444-51892-8.00028-8)

[Schulz JB, Di Prospero Q, Fava E, Mitochondrial function enhancers (2019)](https://doi.org/10.1016/j.mcn.2019.01.001)

[Stamelos G, Truong J, Kemp K, Nrf2 activators in Friedreich ataxia (2019)](https://doi.org/10.1080/13510002.2019.1656205)

[Georgieva M, Stamelos M, Kitis K, Iron homeostasis therapeutics (2020)](https://doi.org/10.1007/s00109-020-01919-5)

[Corben LA, Delatycki MB, Symptom management in Friedreich ataxia (2012)](https://doi.org/10.1016/B978-0-444-51892-8.00030-6)

[Pandolfo M, Schulz JB, Lynch D, Clinical trials in Friedreich ataxia (2023)](https://doi.org/10.1016/j.jns.2023.120061)

[Badadoni M, Ghiardello S, Mascalchi M, Survival analysis in Friedreich ataxia (2011)](https://doi.org/10.1016/j.jns.2011.04.014)

[Delatycki MB, Paris DB, Gardner RJ, Causes of death in Friedreich ataxia (2006)](https://doi.org/10.1007/s00415-006-0123-1)

[Filla A, De Michele G, Cavalcanti F, et al, GAA repeat size and prognosis (2000)](https://doi.org/10.1212/WNL.55.9.1261)

[Harding AE, Late onset Friedreich ataxia (1985)](https://doi.org/10.1136/jnnp.48.2.171)

[Unknown, Schöls L, Zühlke C, Rieß O. Prognostic factors in Friedreich ataxia (1995)](https://doi.org/10.1016/0022-510X(94)

[Epplen C, Epplen JT, Frank G, et al, Early onset and disease severity (1997)](https://doi.org/10.1136/jmg.34.5.382)

[Montermini L, Andermann F, Wessner M, et al, Large GAA repeats and prognosis (1997)](https://doi.org/10.1002/ana.410410517)

[Pousset F, Dambrosi C, Vexler A, et al, Cardiac involvement and prognosis (2018)](https://doi.org/10.1016/j.jacc.2018.06.042)

[Koch H, Ziemann M, Kiwit J, Diabetes and prognosis in Friedreich ataxia (2006)](https://doi.org/10.1016/j.jns.2005.09.010)

[Corben LA, Lynch D, Pandolfo M, Wheelchair dependence in Friedreich ataxia (2011)](https://doi.org/10.1016/j.jns.2011.04.017)

[Niemann L, Huber N, Maier A, Cognitive function in Friedreich ataxia (2015)](https://doi.org/10.1007/s00415-015-7819-5)

[Shanahan J, Ramke J, Jenkins E, Psychological support in Friedreich ataxia (2015)](https://doi.org/10.1007/s10897-014-9780-9)

Genetic Variants

Gene: GAA

| Variant | Clinical Significance | Conditions |
|---|---|---|
| NM_000152.5(GAA):c.956-2_956del | Likely pathogenic | Glycogen storage disease, type II |
| NM_000152.5(GAA):c.701C>A (p.Thr234Lys) | Likely pathogenic | Glycogen storage disease, type II |
| NM_000152.5(GAA):c.679del (p.Asp227fs) | Likely pathogenic | Glycogen storage disease, type II |
| NM_000152.5(GAA):c.547-2A>G | Pathogenic | Glycogen storage disease, type II |
| NM_000152.5(GAA):c.463_464insG (p.Thr155fs) | Likely pathogenic | Glycogen storage disease, type II |
| NM_000152.5(GAA):c.344_345del (p.Gln115fs) | Likely pathogenic | Glycogen storage disease, type II |
| NM_000152.5(GAA):c.2643del (p.Asn882fs) | Likely pathogenic | Glycogen storage disease, type II |
| NM_000152.5(GAA):c.2323del (p.Leu775fs) | Likely pathogenic | Glycogen storage disease, type II |

📖 View canonical wiki page →

Related Entities

diseases-friedreichs-ataxia

▸Metadataorigin_type: v1_polymorphic_backfill

slug	diseases-friedreichs-ataxia
kg_node_id	None
entity_type	disease
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-0cb17a4d7d09
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'diseases-friedreichs-ataxia'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

15%

Debates

0

Incoming

3

Outgoing

8

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Friedreich's Ataxia

Friedreich Ataxia

Overview

Genetics

Gene and Mutation

Friedreich Ataxia

Overview

Genetics

Gene and Mutation

Frataxin Function

Pathophysiology

Mitochondrial Dysfunction

Tissue-Specific Vulnerability

Molecular Cascades

Clinical Features

Neurological Manifestations

Ataxia

Sensory Deficits

Motor Features

Non-Ataxia Features

Cardiac Involvement

Endocrine Manifestations

Musculoskeletal Complications

Disease Course

Diagnosis

Clinical Diagnostic Criteria

Genetic Testing

Biomarkers

Neuroimaging

Management

Disease-Modifying Therapies

Frataxin-Targeting Approaches

Experimental Approaches

Symptomatic Management

Ataxia

Cardiac Management

Diabetes Management

Musculoskeletal Care

Emerging Therapies

Animal Models

Mouse Models

Phenotypic Features

Therapeutic Testing

Research Directions

Prognosis

Life Expectancy

Prognostic Factors

Quality of Life

See Also

External Links

Pathway Diagram

References

Genetic Variants

💬 Discussion